Handelsbanken Fonder AB Purchases 66,713 Shares of DexCom, Inc. $DXCM

Handelsbanken Fonder AB grew its position in DexCom, Inc. (NASDAQ:DXCM) by 13.8% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 551,098 shares of the medical device company’s stock after purchasing an additional 66,713 shares during the quarter. Handelsbanken Fonder AB’s holdings in DexCom were worth $37,083,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in DXCM. Andra AP fonden bought a new stake in shares of DexCom during the second quarter valued at approximately $26,000. Twin Peaks Wealth Advisors LLC bought a new position in DexCom in the 2nd quarter valued at approximately $26,000. SJS Investment Consulting Inc. boosted its stake in DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 384 shares during the last quarter. Financial Consulate Inc. bought a new stake in shares of DexCom in the 3rd quarter worth $29,000. Finally, Sound Income Strategies LLC raised its stake in shares of DexCom by 83.8% in the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after purchasing an additional 285 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 1.3%

DexCom stock opened at $73.43 on Friday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The company has a market cap of $28.26 billion, a P/E ratio of 34.97, a P/E/G ratio of 1.45 and a beta of 1.49. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The business has a 50-day simple moving average of $70.24 and a two-hundred day simple moving average of $69.23.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The company had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter last year, the firm posted $0.45 earnings per share. The firm’s revenue was up 13.1% compared to the same quarter last year. Analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on DXCM shares. Evercore began coverage on DexCom in a report on Tuesday, November 25th. They set an “in-line” rating and a $68.00 price target on the stock. JPMorgan Chase & Co. lowered their target price on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Friday, October 31st. Argus dropped their price target on shares of DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Mizuho boosted their price objective on shares of DexCom from $78.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, February 13th. Finally, Wells Fargo & Company lowered their price objective on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.18.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.